Literature DB >> 25461247

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

David S Lehmann1, Heather J Ribaudo, Eric S Daar, Roy M Gulick, Richard H Haubrich, Gregory K Robbins, Paul I W de Bakker, David W Haas, Paul J McLaren.   

Abstract

BACKGROUND: Efavirenz and abacavir are components of recommended first-line regimens for HIV-1 infection. We used genome-wide genotyping and clinical data to explore genetic associations with virologic failure among patients randomized to efavirenz-containing or abacavir-containing regimens in AIDS Clinical Trials Group (ACTG) protocols. PARTICIPANTS AND METHODS: Virologic response and genome-wide genotype data were available from treatment-naive patients randomized to efavirenz-containing (n=1596) or abacavir-containing (n = 786) regimens in ACTG protocols 384, A5142, A5095, and A5202.
RESULTS: Meta-analysis of association results across race/ethnic groups showed no genome-wide significant associations (P < 5 × 10) with virologic response for either efavirenz or abacavir. Our sample size provided 80% power to detect a genotype relative risk of 1.8 for efavirenz and 2.4 for abacavir. Analyses focused on CYP2B genotypes that define the lowest plasma efavirenz exposure stratum did not show associations nor did analysis limited to gene sets predicted to be relevant to efavirenz and abacavir disposition.
CONCLUSION: No single polymorphism is associated strongly with virologic failure with efavirenz-containing or abacavir-containing regimens. Analyses to better consider context, and that minimize confounding by nongenetic factors, may show associations not apparent here.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25461247      PMCID: PMC4387236          DOI: 10.1097/FPC.0000000000000106

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  46 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

2.  The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

Authors:  Florencia Pereyra; Xiaoming Jia; Paul J McLaren; Amalio Telenti; Paul I W de Bakker; Bruce D Walker; Stephan Ripke; Chanson J Brumme; Sara L Pulit; Mary Carrington; Carl M Kadie; Jonathan M Carlson; David Heckerman; Robert R Graham; Robert M Plenge; Steven G Deeks; Lauren Gianniny; Gabriel Crawford; Jordan Sullivan; Elena Gonzalez; Leela Davies; Amy Camargo; Jamie M Moore; Nicole Beattie; Supriya Gupta; Andrew Crenshaw; Noël P Burtt; Candace Guiducci; Namrata Gupta; Xiaojiang Gao; Ying Qi; Yuko Yuki; Alicja Piechocka-Trocha; Emily Cutrell; Rachel Rosenberg; Kristin L Moss; Paul Lemay; Jessica O'Leary; Todd Schaefer; Pranshu Verma; Ildiko Toth; Brian Block; Brett Baker; Alissa Rothchild; Jeffrey Lian; Jacqueline Proudfoot; Donna Marie L Alvino; Seanna Vine; Marylyn M Addo; Todd M Allen; Marcus Altfeld; Matthew R Henn; Sylvie Le Gall; Hendrik Streeck; David W Haas; Daniel R Kuritzkes; Gregory K Robbins; Robert W Shafer; Roy M Gulick; Cecilia M Shikuma; Richard Haubrich; Sharon Riddler; Paul E Sax; Eric S Daar; Heather J Ribaudo; Brian Agan; Shanu Agarwal; Richard L Ahern; Brady L Allen; Sherly Altidor; Eric L Altschuler; Sujata Ambardar; Kathryn Anastos; Ben Anderson; Val Anderson; Ushan Andrady; Diana Antoniskis; David Bangsberg; Daniel Barbaro; William Barrie; J Bartczak; Simon Barton; Patricia Basden; Nesli Basgoz; Suzane Bazner; Nicholaos C Bellos; Anne M Benson; Judith Berger; Nicole F Bernard; Annette M Bernard; Christopher Birch; Stanley J Bodner; Robert K Bolan; Emilie T Boudreaux; Meg Bradley; James F Braun; Jon E Brndjar; Stephen J Brown; Katherine Brown; Sheldon T Brown; Jedidiah Burack; Larry M Bush; Virginia Cafaro; Omobolaji Campbell; John Campbell; Robert H Carlson; J Kevin Carmichael; Kathleen K Casey; Chris Cavacuiti; Gregory Celestin; Steven T Chambers; Nancy Chez; Lisa M Chirch; Paul J Cimoch; Daniel Cohen; Lillian E Cohn; Brian Conway; David A Cooper; Brian Cornelson; David T Cox; Michael V Cristofano; George Cuchural; Julie L Czartoski; Joseph M Dahman; Jennifer S Daly; Benjamin T Davis; Kristine Davis; Sheila M Davod; Edwin DeJesus; Craig A Dietz; Eleanor Dunham; Michael E Dunn; Todd B Ellerin; Joseph J Eron; John J W Fangman; Claire E Farel; Helen Ferlazzo; Sarah Fidler; Anita Fleenor-Ford; Renee Frankel; Kenneth A Freedberg; Neel K French; Jonathan D Fuchs; Jon D Fuller; Jonna Gaberman; Joel E Gallant; Rajesh T Gandhi; Efrain Garcia; Donald Garmon; Joseph C Gathe; Cyril R Gaultier; Wondwoosen Gebre; Frank D Gilman; Ian Gilson; Paul A Goepfert; Michael S Gottlieb; Claudia Goulston; Richard K Groger; T Douglas Gurley; Stuart Haber; Robin Hardwicke; W David Hardy; P Richard Harrigan; Trevor N Hawkins; Sonya Heath; Frederick M Hecht; W Keith Henry; Melissa Hladek; Robert P Hoffman; James M Horton; Ricky K Hsu; Gregory D Huhn; Peter Hunt; Mark J Hupert; Mark L Illeman; Hans Jaeger; Robert M Jellinger; Mina John; Jennifer A Johnson; Kristin L Johnson; Heather Johnson; Kay Johnson; Jennifer Joly; Wilbert C Jordan; Carol A Kauffman; Homayoon Khanlou; Robert K Killian; Arthur Y Kim; David D Kim; Clifford A Kinder; Jeffrey T Kirchner; Laura Kogelman; Erna Milunka Kojic; P Todd Korthuis; Wayne Kurisu; Douglas S Kwon; Melissa LaMar; Harry Lampiris; Massimiliano Lanzafame; Michael M Lederman; David M Lee; Jean M L Lee; Marah J Lee; Edward T Y Lee; Janice Lemoine; Jay A Levy; Josep M Llibre; Michael A Liguori; Susan J Little; Anne Y Liu; Alvaro J Lopez; Mono R Loutfy; Dawn Loy; Debbie Y Mohammed; Alan Man; Michael K Mansour; Vincent C Marconi; Martin Markowitz; Rui Marques; Jeffrey N Martin; Harold L Martin; Kenneth Hugh Mayer; M Juliana McElrath; Theresa A McGhee; Barbara H McGovern; Katherine McGowan; Dawn McIntyre; Gavin X Mcleod; Prema Menezes; Greg Mesa; Craig E Metroka; Dirk Meyer-Olson; Andy O Miller; Kate Montgomery; Karam C Mounzer; Ellen H Nagami; Iris Nagin; Ronald G Nahass; Margret O Nelson; Craig Nielsen; David L Norene; David H O'Connor; Bisola O Ojikutu; Jason Okulicz; Olakunle O Oladehin; Edward C Oldfield; Susan A Olender; Mario Ostrowski; William F Owen; Eunice Pae; Jeffrey Parsonnet; Andrew M Pavlatos; Aaron M Perlmutter; Michael N Pierce; Jonathan M Pincus; Leandro Pisani; Lawrence Jay Price; Laurie Proia; Richard C Prokesch; Heather Calderon Pujet; Moti Ramgopal; Almas Rathod; Michael Rausch; J Ravishankar; Frank S Rhame; Constance Shamuyarira Richards; Douglas D Richman; Berta Rodes; Milagros Rodriguez; Richard C Rose; Eric S Rosenberg; Daniel Rosenthal; Polly E Ross; David S Rubin; Elease Rumbaugh; Luis Saenz; Michelle R Salvaggio; William C Sanchez; Veeraf M Sanjana; Steven Santiago; Wolfgang Schmidt; Hanneke Schuitemaker; Philip M Sestak; Peter Shalit; William Shay; Vivian N Shirvani; Vanessa I Silebi; James M Sizemore; Paul R Skolnik; Marcia Sokol-Anderson; James M Sosman; Paul Stabile; Jack T Stapleton; Sheree Starrett; Francine Stein; Hans-Jurgen Stellbrink; F Lisa Sterman; Valerie E Stone; David R Stone; Giuseppe Tambussi; Randy A Taplitz; Ellen M Tedaldi; Amalio Telenti; William Theisen; Richard Torres; Lorraine Tosiello; Cecile Tremblay; Marc A Tribble; Phuong D Trinh; Alice Tsao; Peggy Ueda; Anthony Vaccaro; Emilia Valadas; Thanes J Vanig; Isabel Vecino; Vilma M Vega; Wenoah Veikley; Barbara H Wade; Charles Walworth; Chingchai Wanidworanun; Douglas J Ward; Daniel A Warner; Robert D Weber; Duncan Webster; Steve Weis; David A Wheeler; David J White; Ed Wilkins; Alan Winston; Clifford G Wlodaver; Angelique van't Wout; David P Wright; Otto O Yang; David L Yurdin; Brandon W Zabukovic; Kimon C Zachary; Beth Zeeman; Meng Zhao
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

3.  Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W Sagoe; Michael H Court
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

4.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

5.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Authors:  Eric S Daar; Camlin Tierney; Margaret A Fischl; Paul E Sax; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Keith A Pappa; William C Woodward; Kristine Patterson; Hector Bolivar; Constance A Benson; Ann C Collier
Journal:  Ann Intern Med       Date:  2011-02-14       Impact factor: 25.391

6.  Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

Authors:  Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

7.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Journal:  N Engl J Med       Date:  2009-12-01       Impact factor: 91.245

8.  Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits.

Authors:  Ayellet V Segrè; Leif Groop; Vamsi K Mootha; Mark J Daly; David Altshuler
Journal:  PLoS Genet       Date:  2010-08-12       Impact factor: 5.917

9.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321

10.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Authors:  Kimberly Y Smith; Parul Patel; Derek Fine; Nicholaos Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark S Shaefer
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

View more
  6 in total

1.  Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Yang Yang; Gregory E Wilding; Gene D Morse
Journal:  Ther Drug Monit       Date:  2017-12       Impact factor: 3.681

Review 2.  Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Authors:  Ritika Kapoor; Wei Chuen Tan-Koi; Yik-Ying Teo
Journal:  Eur J Hum Genet       Date:  2016-08-31       Impact factor: 4.246

3.  Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.

Authors:  Marijana Vujkovic; Scarlett L Bellamy; Athena F Zuppa; Marc Gastonguay; Ganesh S Moorthy; Bakgaki R Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Brian L Strom; Richard Aplenc; Gregory P Bisson; Robert Gross
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-01       Impact factor: 3.731

4.  Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Authors:  Laura Dickinson; Janaki Amin; Laura Else; Marta Boffito; Deirdre Egan; Andrew Owen; Saye Khoo; David Back; Catherine Orrell; Amanda Clarke; Marcelo Losso; Praphan Phanuphak; Dianne Carey; David A Cooper; Sean Emery; Rebekah Puls
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 5.  Host genetic variation and HIV disease: from mapping to mechanism.

Authors:  Vivek Naranbhai; Mary Carrington
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

6.  Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.

Authors:  Monkgomotsi J Maseng; Leabaneng Tawe; Prisca K Thami; Kaelo K Seatla; Sikhulile Moyo; Axel Martinelli; Ishmael Kasvosve; Vladimir Novitsky; Max Essex; Gianluca Russo; Simani Gaseitsiwe; Giacomo M Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2021-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.